경비 약물전달 시장 규모는 2024년 644억 5,120만 달러에서 예측 기간 중 CAGR 6.24%로 추이하며, 2032년에는 1,042억 4,863만 달러에 달할 것으로 예측됩니다.
이러한 성장은 주로 신경질환, 호흡기 질환, 중증 알레르기 질환, 안과 질환과 같은 만성질환의 유병률 증가에 의해 주도되고 있습니다. 빠른 효과가 있고 비침습적인 약물 투여법에 대한 수요가 증가하고 있는 것도 시장 확대에 기여하고 있으며, 특히 비강 투여는 흡수가 빠르고 사용이 용이하다는 장점으로 환자의 복약 순응도 및 치료 효과 향상에 기여하고 있습니다. 또한 연구개발 활동의 활성화와 주요 기업의 제품 출시 증가도 이 분야의 기술 혁신을 가속화하고 있습니다. 이러한 발전은 보다 효율적이고 표적화된 비강 치료의 개발을 촉진하고, 시장을 활성화하고 경쟁력을 강화하는 데 기여하고 있습니다. 이러한 일련의 추세는 시장의 지속적인 성장에 유리한 환경을 형성하고 있으며, 2025-2032년까지 강력하고 안정적인 확장이 예상됩니다.
비강내 약물전달 시장 역학:
세계보건기구(WHO)가 2024년 발표한 자료에 따르면 2023년 전 세계 간질 환자 수는 약 5,000만 명에 달할 것으로 예상되며, 신경질환 중 가장 흔한 질환 중 하나가 될 것으로 예측됩니다. 특히 약 80%가 중저소득 국가에 집중되어 있으며, 이들 지역에서는 적시에 치료받을 수 있는 접근성이 여전히 제한적입니다. 이러한 환경에서 의료진의 감독 없이도 사용할 수 있는 실용적이고 즉각적인 비강 투여는 효과적인 대안이 될 수 있습니다. 이러한 간질 환자 증가가 시장 성장을 촉진하고 있으며, 경구용 약물은 간질 환자의 발작에 대한 급성기 대응에 사용되고 있습니다.
마찬가지로 우울증도 여전히 전 세계적인 건강 문제입니다. 세계보건기구(WHO)에 따르면 2023년 전 세계에서 약 2억 8,000만 명이 우울증을 앓고 있는 것으로 추산됩니다. 비강 치료는 치료 저항성 우울증에 대한 효과적인 치료법으로 부상하고 있으며, 빠른 증상 완화와 간편한 투여법으로 특히 외래 및 응급 현장에서 수요를 창출하고 있습니다. 이로 인해 비강내 약물전달 솔루션에 대한 수요가 증가하고 있습니다.
세계 당뇨병 부담도 빠르게 증가하고 있습니다. 국제당뇨병연맹(2023년)에 따르면 2021년 당뇨병 환자 수는 5억 3,700만 명, 2030년 6억 4,300만 명, 2045년 7억 8,300만 명으로 증가할 것으로 예측했습니다. 글루카곤과 같은 호르몬의 혁신적인 경구용 제제는 주사 요법에 대한 비침습적이고 즉각적인 대체요법을 제공하여 간 대사를 우회하면서 당뇨병 환자의 급성 저혈당을 관리할 수 있도록 돕습니다. 따라서 당뇨병 환자 증가는 비강 약물전달 시장의 성장을 가속하고 있습니다.
세계에서 당뇨병의 부담도 빠르게 증가하고 있습니다. 국제당뇨병연맹(IDF)의 2023년 자료에 따르면 2021년 20-79세 성인 5억 3,700만 명이 당뇨병을 앓고 있으며, 이 수치는 2030년 6억 4,300만 명, 2045년 7억 8,300만 명으로 늘어날 것으로 예측됩니다. 글루카곤과 같은 호르몬을 비강을 통해 투여하는 혁신적인 제제는 비침습적이고 즉각적인 주사 대안을 제공하며, 간 1차 통과 대사를 피하면서 저혈당의 급성 관리에 기여하고 있습니다. 이 때문에 당뇨병 증가는 시장 성장을 더욱 촉진하고 있습니다.
또한 만성통증과 편두통은 전 세계에서 많은 사람들에게 영향을 미치고 있습니다. 유럽통증학회연합(2023년)에 따르면 2023년 약 1억 5,000만 명의 유럽인이 만성통증에 시달리고 있으며, WHO의 추산에 따르면 2021년 편두통 및 기타 두통 질환이 전 세계 약 31억 명에게 영향을 미쳤다고 합니다. 경구용 약물은 급성 편두통 발작 관리에 사용되며, 소화관을 거치지 않고 빠르게 효과를 발휘하므로 그 수요가 증가하고 있습니다.
세계의 경비 약물전달 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회의 분석, 법규제 환경, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
Intranasal Drug Delivery Market by Dosage Form (Spray, Drops and Liquids, Gels, and Powders), Container (Pressurized and Non-pressurized), System (Unit-dose Systems, Bi-Dose Systems, and Multi-dose Systems), Application (Respiratory Disorders, Neurological Disorders, Infectious Diseases, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to The growing prevalence of chronic diseases and increasing R&D activities and product launches by key players in the domain of intranasal drug delivery.
The intranasal drug delivery market was valued at USD 64,451.20 million in 2024, growing at a CAGR of 6.24% during the forecast period from 2025 to 2032 to reach USD 104,248.63 million by 2032. This growth is primarily driven by the rising prevalence of chronic diseases, including neurological, respiratory, severe allergic, and ophthalmic disorders. The increasing demand for rapid-onset, non-invasive drug administration methods is also contributing to market expansion, as intranasal delivery offers fast absorption and ease of use, key factors in enhancing patient compliance and therapeutic outcomes. Moreover, heightened R&D activities and a surge in product launches by key industry players are further accelerating innovation in the field. These advancements are creating a dynamic and competitive landscape, fostering the development of more efficient and targeted intranasal therapies. Together, these trends are shaping a favorable environment for the sustained growth of the intranasal drug delivery market, positioning it for robust and consistent expansion throughout the forecast period from 2025 to 2032.
Intranasal Drug Delivery Market Dynamics:
According to the World Health Organization (2024), in 2023, epilepsy affected approximately 50 million people worldwide, making it one of the most common neurological disorders. Notably, around 80% of these cases occurred in low- and middle-income countries, where access to timely treatment remains limited. In such settings, intranasal drug delivery provides a practical, fast-acting alternative that can be administered without medical supervision. Such growing cases of epilepsy are driving the market growth as intranasal drug delivery is used for the acute treatment of intermittent episodes of increased seizure activity in patients with epilepsy.
Similarly, depression remains a major global health concern. As per WHO (2023), in 2023, an estimated 280 million people worldwide were living with depression. Intranasal therapies emerged as effective treatments for treatment-resistant depression, offering rapid symptom relief and easy administration, especially in outpatient and emergency care environments thereby creating the demand for intranasal drug delivery solutions.
The global diabetes burden is also rising rapidly. According to the International Diabetes Federation (2023), in 2021, there were 537 million adults (aged 20-79) living with diabetes, a number projected to increase to 643 million by 2030 and 783 million by 2045. Innovative intranasal formulations of hormones like glucagon provide a non-invasive, fast-acting alternative to injectable therapies, helping manage acute hypoglycemia in diabetic patients while bypassing hepatic metabolism. Therefore, rising cases of diabetes are driving the growth of the intranasal drug delivery market.
Additionally, chronic pain and migraine continue to affect large populations worldwide. According to the European Pain Federation (2023), in 2023, approximately 150 million people in Europe suffered from chronic pain. Meanwhile, the WHO (2024), estimated that migraine and other headache disorders affected 3.1 billion people globally in 2021. The demand for intranasal drug delivery solutions is increasing due to rising cases of migraine as these devices manage acute migraine attacks, offering quick relief by bypassing the gastrointestinal tract.
According to NHS England (2023), approximately 5.4 million individuals received treatment for asthma in 2023, with around 160,000 new diagnoses recorded annually in the United Kingdom. This rising prevalence of asthma is a significant driver of growth in the intranasal drug delivery market. Intranasal delivery presents a promising approach for asthma management, offering advantages such as ease of administration, rapid onset of action, and the ability to bypass first-pass metabolism. These benefits not only improve patient compliance but also enhance therapeutic efficiency, further contributing to the growing adoption of intranasal drug delivery systems in the treatment of respiratory conditions like asthma.
Conditions like depression, epilepsy, chronic pain, diabetes, and respiratory disorders often require medications that are either rapidly metabolized by the liver or difficult to administer orally during acute episodes. Intranasal drug delivery offers key advantages in such cases, including rapid absorption, avoidance of first-pass hepatic metabolism, and reduced side effects due to the lower doses required. Therefore, the growing prevalence of chronic diseases such as neurological disorders, respiratory conditions, and diabetes is significantly driving the growth of the intranasal drug delivery market.
The intranasal drug delivery market is further propelled by ongoing product approvals and launches from key industry players, reinforcing innovation and expanding treatment options. For example, in February 2025, Lupin Limited announced it had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution. This product is indicated for the symptomatic relief of rhinorrhea associated with both allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Similarly, in April 2024, Amneal Pharmaceuticals received U.S. FDA approval for its Over-the-counter (OTC) Naloxone Hydrochloride Nasal Spray, intended for the emergency treatment of opioid overdose. These developments not only underscore the growing adoption of intranasal formulations but also highlight the increasing focus on accessibility, patient convenience, and rapid therapeutic response key factors fueling the market's sustained growth.
However, the complexities and limitations associated with the intranasal drug administration and stringent regulatory requirements for product approval, among others are some of the key constraints that may limit the growth of the intranasal drug delivery market.
Intranasal Drug Delivery Market Segment Analysis:
Intranasal Drug Delivery Market by Dosage Form (Spray, Drops and Liquids, Gels, and Powders), Container (Pressurized and Non-pressurized), System (Unit-dose Systems, Bi-Dose Systems, and Multi-dose Systems), Application (Respiratory Disorders, Neurological Disorders, Infectious Diseases, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the dosage form segment of the intranasal drug delivery market, the spray category is estimated to account for the largest market share in 2024. This robust growth is primarily driven by the increasing prevalence of respiratory diseases, severe allergic reactions, ophthalmic disorders, and neurological conditions, coupled with the multiple clinical and practical advantages offered by nasal sprays.
Nasal sprays are favored for their non-invasive, needle-free application, offering ease of administration and rapid onset of action are the factors that significantly enhance patient compliance and therapeutic efficiency. The nasal mucosa's highly vascularized and permeable surface enables efficient systemic absorption of drugs while bypassing the first-pass hepatic metabolism and avoiding gastrointestinal degradation. This leads to improved bioavailability, especially for drugs that are unstable or poorly absorbed through oral routes.
Moreover, nasal sprays are increasingly being utilized in the treatment of central nervous system (CNS) disorders. Their ability to deliver drugs via the olfactory and trigeminal nerve pathways allows for direct access to the brain, making them particularly effective in treating acute neurological conditions such as migraines, seizures, and opioid overdoses, where immediate therapeutic intervention is critical.
With the global burden of neurological diseases on the rise, leading pharmaceutical companies are intensifying their investments in research and development to introduce advanced intranasal spray formulations targeting these conditions. For example, in March 2023, Pfizer Inc. received FDA approval for ZAVZPRET(TM) (zavegepant), a CGRP receptor antagonist nasal spray indicated for the acute treatment of migraine, with or without aura, in adults. Similarly, in August 2023, Emergent BioSolutions launched NARCAN(R) Naloxone HCl Nasal Spray 4 mg, an over-the-counter (OTC) product designed for the emergency treatment of opioid overdose. These product innovations and regulatory milestones underscore the increasing clinical relevance of nasal sprays in both urgent care and chronic disease management. As such, the spray segment is poised for substantial expansion, driven by a convergence of therapeutic demand, technological advancement, and regulatory support.
Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of intranasal drug delivery across the globe.
North America is expected to dominate the overall intranasal drug delivery market:
North America is expected to hold the largest share of the intranasal drug delivery market in 2024, driven by several key factors. The region's dominance is primarily attributed to the rising prevalence of neurological, respiratory, and diabetes, which has created a growing demand for more effective and patient-friendly drug delivery solutions. Additionally, the increasing preference for rapid-onset therapies and the convenience of self-administration is significantly boosting the adoption of intranasal drug delivery systems across the region. Moreover, increase in regulatory approvals and new product launches by leading pharmaceutical companies with a strong pipeline of intranasal formulations, coupled with favorable healthcare infrastructure and awareness. Collectively, these factors are expected to sustain North America's leading position in the global market.
As per the data from the National Institute of Health (2023), in 2022, it was estimated that more than one in five adults were living with a mental illness (59.3 million) with 21 million people suffering from one major depressive disorder. Similarly, data from the Government of Canada (2023), in 2022, approximately 5 million people were suffering from mental disorders including major depressive disorders, anxiety, and seizures among others. Intranasal drug delivery devices with drugs are used for treatment-resistant depression and major depressive disorder with suicidal ideation.
According to the Centers for Disease Control and Prevention (2024), in 2022, approximately 2.9 million adults aged 18 and older in the U.S. reported having active epilepsy.
Additionally, data from the Anxiety & Depression Association of America (2022), revealed that 2 to 3% of individuals in the country experienced panic disorder, with women being twice as likely to be affected as men. Furthermore, generalized anxiety disorder (GAD) impacted around 6.8 million adults, or 3.1% of the U.S. population, underscoring the widespread burden of anxiety-related conditions.
The increasing incidence of such neurological and psychiatric disorders necessitates fast-acting, non-invasive treatment options, for which intranasal drug delivery offers a highly effective solution.
According to the Asthma and Allergy Foundation of America (2023), more than 27 million people in the United States were living with asthma in 2022, accounting for approximately 1 in every 12 individuals. Additionally, over 2 million adults aged 18 or older were affected by asthma. Data from the Allergy & Asthma Network (2023), further supported this, indicating that more than 26 million people, including 7% of adults and 6.5% of children, were living with asthma across the country.
Similarly, according to the Centers for Disease Control and Prevention (CDC, 2024), an estimated 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD). The data from the American Lung Association (2023), reported that 1.7 million individuals were diagnosed with COPD and other respiratory diseases, representing 4.6% of the U.S. population. The growing prevalence of asthma, COPD, and related respiratory conditions has led to a surging demand for intranasal drug delivery, which provides effective symptom relief and helps control disease progression.
The rising prevalence of asthma and chronic obstructive pulmonary disease (COPD) is driving growth in the intranasal drug delivery market in the region, as patients seek fast-acting, non-invasive therapies to manage respiratory symptoms like nasal congestion and airway inflammation. Intranasal corticosteroids and decongestants provide targeted relief with fewer systemic side effects, enhancing patient compliance and treatment effectiveness.
In addition to disease prevalence, regulatory advancements and product innovations are further fueling market growth. For instance, in September 2024, AstraZeneca announced that FluMist(R), the only self-administered influenza vaccine, was approved in the U.S. This needle-free nasal spray can be self-administered by adults up to 49 years old or administered by a caregiver to individuals aged 2-17, marking a major step forward in patient-friendly vaccine delivery.
Intranasal Drug Delivery Market Key Players:
Some of the key market players operating in the intranasal drug delivery market include Pfizer Inc., Johnson & Johnson Services, Inc., EMERGENT, UCB S.A., GSK plc, Amphastar Pharmaceuticals, Inc., Neurelis, Inc., Hikma Pharmaceuticals PLC, Perrigo Company, ARS Pharmaceuticals Operations, Inc., AstraZeneca, Therakind, AFT Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Impel Pharmaceuticals LLC, Endo, Inc., Procter & Gamble, Teleflex Incorporated, Viatris, Inc., Amneal Pharmaceuticals LLC, and others.
Recent Developmental Activities in the Intranasal Drug Delivery Market:
Key takeaways from the intranasal drug delivery market report study
Target audience who can benefit from this intranasal drug delivery market report study
Frequently Asked Questions for the Intranasal Drug Delivery Market: